Cargando…
Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy
One-third of patients with epilepsy continue to have seizures despite current treatments, indicating the need for better antiseizure medications with novel mechanisms of action. Ezogabine (retigabine) has recently been approved for adjunctive treatment of partial-onset seizures in adult patients wit...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413039/ https://www.ncbi.nlm.nih.gov/pubmed/22888276 http://dx.doi.org/10.2147/DHPS.S28814 |
_version_ | 1782240019063242752 |
---|---|
author | Ciliberto, Michael A Weisenberg, Judith LZ Wong, Michael |
author_facet | Ciliberto, Michael A Weisenberg, Judith LZ Wong, Michael |
author_sort | Ciliberto, Michael A |
collection | PubMed |
description | One-third of patients with epilepsy continue to have seizures despite current treatments, indicating the need for better antiseizure medications with novel mechanisms of action. Ezogabine (retigabine) has recently been approved for adjunctive treatment of partial-onset seizures in adult patients with epilepsy. Ezogabine utilizes a novel mechanism of action, involving activation of specific potassium channels. The most common side effects of ezogabine are shared by most antiseizure medications and primarily consist of central nervous system (CNS) symptoms, such as somnolence, dizziness, confusion, and fatigue. In addition, a small percentage of patients on ezogabine experience a unique adverse effect affecting the bladder, which results in urinary hesitancy; thus, patients on ezogabine should be monitored carefully for potential urological symptoms. Overall, ezogabine appears to be well tolerated and represents a reasonable new option for treating patients with intractable epilepsy. |
format | Online Article Text |
id | pubmed-3413039 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-34130392012-08-10 Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy Ciliberto, Michael A Weisenberg, Judith LZ Wong, Michael Drug Healthc Patient Saf Review One-third of patients with epilepsy continue to have seizures despite current treatments, indicating the need for better antiseizure medications with novel mechanisms of action. Ezogabine (retigabine) has recently been approved for adjunctive treatment of partial-onset seizures in adult patients with epilepsy. Ezogabine utilizes a novel mechanism of action, involving activation of specific potassium channels. The most common side effects of ezogabine are shared by most antiseizure medications and primarily consist of central nervous system (CNS) symptoms, such as somnolence, dizziness, confusion, and fatigue. In addition, a small percentage of patients on ezogabine experience a unique adverse effect affecting the bladder, which results in urinary hesitancy; thus, patients on ezogabine should be monitored carefully for potential urological symptoms. Overall, ezogabine appears to be well tolerated and represents a reasonable new option for treating patients with intractable epilepsy. Dove Medical Press 2012-07-26 /pmc/articles/PMC3413039/ /pubmed/22888276 http://dx.doi.org/10.2147/DHPS.S28814 Text en © 2012 Ciliberto et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Ciliberto, Michael A Weisenberg, Judith LZ Wong, Michael Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy |
title | Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy |
title_full | Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy |
title_fullStr | Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy |
title_full_unstemmed | Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy |
title_short | Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy |
title_sort | clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413039/ https://www.ncbi.nlm.nih.gov/pubmed/22888276 http://dx.doi.org/10.2147/DHPS.S28814 |
work_keys_str_mv | AT cilibertomichaela clinicalutilitysafetyandtolerabilityofezogabineretigabineinthetreatmentofepilepsy AT weisenbergjudithlz clinicalutilitysafetyandtolerabilityofezogabineretigabineinthetreatmentofepilepsy AT wongmichael clinicalutilitysafetyandtolerabilityofezogabineretigabineinthetreatmentofepilepsy |